Replies to post #18453 on NDT Pharmaceuticals Inc (NDTP)

[Ecomike]

I must assume you Mean Edward Mathias co-founder and co-funder of the the Carlyle Group, where he was last reported to be managing 200 Billion dollars of International investment funds, and Larry Kubin of Donnelley Financials Solutions that does SEC filings packaging for firms like Microsoft and Mr Yarbrough of the Cision company firm sold off of Nasdaq last year for over 1 Billion dollars?



https://www.bloomberg.com/profile/person/1524693

[Ecomike]

Sounds like you accusing these folks of being bad people?

Is that true?

James B.Hovis

James B.Hovis is the acting CEO of NDT Pharmaceuticals. Jim was responsible for negotiating the agreement between NDT and the University Of Pennsylvania’s Center for Brain Injury and Repair at the Perelman School of Medicine. Additionally, Mr. Hovis directs the NDT's acquisition and financing activities. Mr. Hovis has over 30 years of experience involving a wide range of corporate financings and refinancings, including debt and equity private placements, mergers and acquisitions (including product acquisitions, leveraged and management buyouts), divestitures, sales of assets or stock, restructurings and reorganizations. His professional background has included a strong emphasis on developing business entities in a number of different industries.

Dr. Mark Kester

Dr. Mark Kester is a Professor of Pharmacology and the Director of the NanoSTAR Institute of the University of Virginia. Mark plays an integral role as Scientific Advisor to the company. He was previously the G. Thomas Passananti Professor of Pharmacology at Penn State Hershey College of Medicine and the inaugural Director of the Penn State Center for NanoMedicine and Materials.

Dr. Kester’s research interests include the design, characterization and validation of nanotechnologies for targeted drug delivery. His laboratory has evaluated nanoliposomes, nanodendrimers and nanocolloids as effective drug delivery vehicles for pharmacological and molecular agents. Recent work focuses on nontoxic nanoscale systemic delivery systems for hydrophobic pro-apoptotic lipids as well as siRNAs that target mutated tumorigenic proteins.

Dr. Kester has consulted with, or founded, several companies that have the license to his nano”Solutions”.

In addition, Dr. Kester is a co-author of Integrated Pharmacology, published by Elsevier, Ltd., which was recognized as a "highly commended textbook" by the British Medical Society.
Edward J. Mathias

Edward J. Mathias is a senior Managing Director of The Carlyle Group and a member of Carlyle's Board of Directors. Mr. Mathias serves as an advisor to senior Management and is a member of the investment committees for Carlyle Growth, Asian Growth, European Technology, Middle East Northern Africa, Mexico Buyout and Sub-Saharan Africa funds.

Lawrence W. Kubin Jr.

Lawrence W. Kubin Jr. brings 28 years of business development and sales experience in Capital Markets, M&A and SEC Reporting services with DFS. Mr. Kubin had served on the board of Coral Networks, a data integration company.

Prior to working for DFS , Mr. Kubin had played in the National Football League with the Washington Redskins (Super Bowl XVll & XVlll), Buffalo Bills, & Tampa Bay Buccaneers. Larry is active in the retired NFL players association and is involved in concussion (Traumatic Brain Injury) related studies & research and solutions.

[snpwfan]

Interesting here boomer- James B Hovis has been in trouble before with the SEC before. https://www.sec.gov/litigation/aljdec/id307jtk.pdf

He is doing the same thing with NDTP that he did with PHLO. He is using 3 hotel room addresses as his office address and that is a big no-no.

I have a family member that used to work with Larry Kubin. I am going to work to get an answer as to whether anybody is working on this or not.